Hologic’s Aptima SARS-CoV-2 assay upgraded its Emergency Use Authorization (EUA), granted in May 2020, to full a US Food and Drug Administration 510(k) clearance on 18 February.
Hologic Upgrades Aptima SARS-Cov-2 Assay Authorization To Full FDA Approval
Molecular Diagnostic Assay Secures FDA 510(k) Clearance
Hologic attains full US Food and Drug Administration 510(k) clearance for its Aptima SARS-CoV-2 assay, which reached market under an Emergency Use Authorization (EUA). Overall, Hologic’s “best-performing” molecular diagnostic business continues to grow despite the decline in revenue for COVID-19 assays and related items.
More from Business
More from Policy & Regulation
The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.
• By
A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.
• By
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.